What do EBV, HPV or hepatitis status have to do with immunotherapy — and why does your oncologist check them?

EBV, HPV, and hepatitis B or C status are checked because these viruses can shape both how a tumour behaves and how safely certain cancer treatments can be given. Nasopharyngeal cancer is frequently EBV-driven, cervical and oropharyngeal (throat/tonsil) cancers are often HPV-related, and hepatitis B or C is a common underlying cause of liver cancer in India — all cancers seen regularly in this region.

Checking viral status is part of the standard diagnostic work-up for these cancers, following NCCN and ASCO guidance, and it also flags anything your oncology team should monitor more closely once treatment begins — particularly active hepatitis.

This page explains what these tests are and why they're ordered, in general terms. It does not, and cannot, interpret your individual report — that conversation belongs with the oncologist who ordered the test and knows your complete clinical picture.

Not reliably on its own. HPV-positive oropharyngeal cancer is generally associated with a more favourable overall prognosis compared with HPV-negative disease of the same site, and EBV-positive tumours are an active research area for checkpoint inhibitor response. Neither, however, is an approved stand-alone eligibility test the way PD-L1 or MSI-High/dMMR status is.

Your oncology team weighs viral status alongside the biomarkers that do have approved eligibility thresholds, plus your cancer type, stage and overall health — it adds context to the picture rather than deciding treatment by itself.

Where evidence for a specific virus and cancer combination is still developing, your oncologist will say so plainly rather than presenting it as settled.

Viral status is one part of a bigger biomarker picture. For the eligibility biomarkers that most directly decide immunotherapy use, see PD-L1 testing and MSI-High and dMMR results.

Yes, particularly for hepatitis B and C. Active or past hepatitis B carries a recognised risk of viral reactivation when the immune system is modulated — including with steroids sometimes used to manage immune-related side effects — so liver function and hepatitis B viral load are checked more closely, and antiviral cover may be arranged with a hepatologist before or alongside immunotherapy.

Hepatitis C is generally treatable with modern oral antivirals and is monitored through liver function tests rather than treated as an automatic reason to withhold immunotherapy. EBV and HPV status, by contrast, mainly inform diagnosis and prognosis rather than changing day-to-day safety monitoring during treatment.

This is monitoring guidance in general terms, not a decision about your individual case — never start, stop, or adjust any treatment for a viral condition without your treating team's direction.

In a proportion of patients, yes. Hepatitis B or C is not automatically a reason to withhold immunotherapy, but it does change how treatment is planned and monitored. Your oncology team typically coordinates with a hepatologist to check viral load and liver function before starting, arranges antiviral therapy where indicated for hepatitis B, and schedules more frequent liver function checks once treatment is underway.

The exact plan depends on how active the hepatitis is, your overall liver function, and the cancer being treated — which is exactly why this is a conversation with your treating team rather than a rule that applies the same way to everyone. CION coordinates hepatitis and related viral testing with accredited partner laboratories rather than running it in-house.

CION coordinates EBV, HPV and hepatitis B/C testing with accredited partner laboratories, and where hepatitis is identified, our oncology team coordinates with a hepatologist as part of your overall treatment planning. For the fuller picture of how immunotherapy is used and monitored at CION, see Immunotherapy at CION Cancer Clinics.

This page explains EBV, HPV and hepatitis testing terminology in general terms and does not interpret any individual report. Viral-status testing is coordinated at accredited partner laboratories, not run in-house. None of these results, on their own, guarantee that immunotherapy will or will not work, or that it will or will not be given — only your treating oncologist, reviewing your complete case, can advise on eligibility and next steps.

Thousands have made sense of their biomarker reports with us

A report full of unfamiliar terms can feel like it's deciding everything on its own. Take the first step today — our team walks this part of the journey with you.